Serum thyroid hormone concentrations and breast cancer risk: an extended cohort study with time-varying exposure analysis
In a large Korean cohort study, an extended analysis using time-varying exposure modeling confirmed a consistent but attenuated inverse association between euthyroid-range TSH and breast cancer risk, particularly in postmenopausal women, while failing to replicate a previously reported positive association between elevated FT4 and breast cancer.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Breast cancer remains the most frequently diagnosed cancer among women worldwide, and in East Asian populations, including South Korea, the number of new cases continues to rise. While doctors and scientists have long understood that factors like age, family history, and body weight play major roles in a woman's risk, the search for other clues is ongoing. One area of particular interest involves the thyroid, a small butterfly-shaped gland in the neck that acts as the body's thermostat, regulating metabolism through hormones. Two specific chemicals produced by this system are thyroid-stimulating hormone, which tells the gland when to work, and free thyroxine, the active hormone that travels through the blood to tissues. Because these hormones influence how cells grow and divide, researchers have wondered if subtle shifts in their levels might also nudge the risk of developing breast cancer, even in women whose thyroid function appears normal on standard tests.
A team of researchers set out to investigate this connection with a massive, long-term look at the health of over 162,000 Korean women. In a previous study involving a smaller group, they had found two intriguing patterns: women with slightly higher levels of thyroid-stimulating hormone within the normal range seemed to have a lower risk of breast cancer, while those with unusually high levels of free thyroxine appeared to have a higher risk. However, that earlier work relied on a single blood test taken at the start of the study and on women reporting their own health outcomes, which can sometimes be inaccurate. To get a clearer picture, the researchers returned to the data with a much larger group, tracking participants from 2011 through 2024. Crucially, they did not just look at the first blood test; they updated their view of each woman's hormone levels every time she returned for a check-up, creating a dynamic picture of her health over time. They also linked their records directly to the national cancer registry, ensuring that every case of breast cancer was confirmed by official medical records rather than self-reporting.
The results of this expanded analysis offered a more nuanced story than the first one. When the researchers looked at the women with normal thyroid function, they found that those with higher levels of thyroid-stimulating hormone did indeed show a trend toward lower breast cancer risk, but the effect was weaker than previously thought. It was not a dramatic drop in danger, but a gentle, consistent slope where higher hormone levels correlated with slightly fewer cases. This pattern was most noticeable in women who had gone through menopause, suggesting that the relationship between thyroid hormones and breast tissue might change as the body ages. However, the second finding from the earlier study did not hold up. The idea that high levels of free thyroxine increase breast cancer risk disappeared when the researchers accounted for repeated measurements over time. In the new analysis, women with high free thyroxine levels did not show a higher risk of developing the disease.
The shift in findings regarding free thyroxine highlights a key lesson about how we measure biological signals in the body. Hormone levels can fluctuate from day to day or even hour to hour due to stress, diet, or minor illness. A single blood test captures only a fleeting moment, like a snapshot of a moving car. If a woman happens to be tested during a temporary spike in her hormone levels, a one-time study might mistakenly label her as having a permanent condition. By updating the data every time a woman returned for a check-up, the researchers could see that many of those high readings were temporary blips rather than sustained states. This suggests that the earlier link between high free thyroxine and cancer risk may have been an illusion created by these temporary fluctuations. In contrast, the relationship between thyroid-stimulating hormone and breast cancer appeared more stable, as the pattern remained consistent whether the researchers looked at a single snapshot or the full, moving picture of repeated tests.
The study also revealed that the type of breast cancer matters. When the researchers focused only on invasive cancers, which are the more serious form that can spread, the protective link with higher thyroid-stimulating hormone levels became slightly stronger. This implies that the hormone might play a specific role in the development of these invasive tumors, rather than the early, non-invasive changes that sometimes occur. While the study could not determine exactly how this happens, the researchers noted that thyroid hormones share some structural similarities with estrogen, a hormone known to fuel breast cancer growth. It is possible that in postmenopausal women, when estrogen levels drop, the thyroid hormones take on a more significant role in regulating cell growth, and higher levels of the stimulating hormone might act as a brake on that process.
Ultimately, this large-scale investigation confirms that the thyroid is likely involved in the complex story of breast cancer risk, but the details are more subtle than previously believed. The connection with thyroid-stimulating hormone appears real but modest, particularly for women after menopause, while the earlier alarm about high free thyroxine levels was likely a false signal caused by the natural variability of hormone levels over time. The work underscores the importance of looking at health data over a long period rather than relying on a single moment in time. For the women in this study, and for the millions of others whose health is monitored, the takeaway is that while thyroid health is important, the relationship between these specific hormones and breast cancer is a gentle, long-term influence rather than a sudden switch that flips risk up or down.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.